Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an investigational, preservative-free lubricating eye drop developed by Johnson & Johnson Vision Care, Inc. for the treatment of dry eye symptoms. The formulation is delivered via the Novelia® multidose bottle system, a specialized dropper that maintains sterility without the need for traditional preservatives like benzalkonium chloride. The solution contains a combination of lubricants, including Polyethylene Glycol 400 and Sodium Hyaluronate, along with an electrolyte balance (Sodium, Potassium, Calcium, and Magnesium chlorides) and a borate buffering system. It is designed to provide mechanical lubrication to the ocular surface and supplement the tear film to alleviate dryness and irritation. The product was evaluated in a Phase 2 clinical trial (NCT05661851) comparing its safety and efficacy to Blink® Tears in non-contact lens wearers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on investigational lubricating eye drop (Johnson & Johnson Vision Care).